Orion Q1 2026 slides: strong profit growth offset by investor concerns

Finnish pharmaceutical company Orion Oyj (HEL:ORNBV) presented robust first-quarter 2026 results on April 23, showcasing significant revenue and profitability gains driven by its oncology portfolio, even as the company’s stock declined sharply on investor concerns about future challenges.

Orion delivered strong financial performance across all key metrics in the first quarter of 2026. Net sales reached €417.7 million, representing a 17.8% increase from €354.6 million in the same period last year. More impressively, operating profit surged 47.3% to €114.8 million from €77.9 million, while the operating margin expanded to 27.5% from 22.0%.

The company’s earnings per share climbed 47.4% to €0.64 from €0.44 in Q1 2025, reflecting the strong operational leverage in the business model. As illustrated in the following financial performance comparison:

Despite these positive results, Orion’s stock fell approximately 5.7% following the announcement, trading at €69.17 after closing at €73.35 the previous day. The stock has traded in a 52-week range between €51.80 and €75.40, suggesting the recent decline represents a pullback from near-peak valuations.

The company’s revenue growth was broadly based across its business segments, as shown in the net sales bridge breakdown. The Innovative Medicines division contributed the lion’s share with €52.5 million in incremental sales, followed by Branded Products (+€5.2 million), Generics and Consumer Health (+€1.9 million), Animal Health (+€1.1 million), and Fermion (+€1.8 million).

The operating profit expansion was particularly noteworthy, driven by a €40.8 million increase in royalty income, primarily from Nubeqa®, the company’s flagship prostate cancer treatment developed in partnership with Bayer. However, this gain was partially offset by €15.0 million in higher fixed costs and €9.3 million in negative impacts from pricing pressures, cost of goods sold, product mix, and foreign exchange fluctuations.

The Innovative Medicines segment, which now accounts for 36% of total net sales, posted exceptional growth of 53.6% to reach €150.3 million in Q1 2026. Nubeqa® alone generated €144.9 million in sales, up 58.4% year-over-year, cementing its position as Orion’s primary growth engine.

The quarterly trend for Nubeqa® shows sustained momentum, with sales comprising both royalty income from Bayer’s global commercialization efforts and direct product sales to Bayer. While Q1 2026 sales of €145 million represented a sequential decline from the exceptional Q4 2025 performance of €213 million, the year-over-year comparison demonstrates strong underlying growth.

Nubeqa® now represents the company’s largest product by a significant margin, with sales nearly three times larger than the second-ranked Easyhaler® product portfolio at €48.3 million.

Beyond Innovative Medicines, Orion’s Branded Products division grew 6.8% to €82.2 million, driven primarily by respiratory products. The company highlighted that Easyhaler® budesonide-formoterol benefited from recent changes in treatment guidelines favoring combination products over monotherapy approaches. The Women’s Health category also showed strong momentum with 14% growth.

The Generics and Consumer Health segment, representing 32% of total sales, posted modest 1.4% growth to €133.5 million. Management noted steady performance across both generic prescription drugs and consumer health products, though this segment faces ongoing pricing pressures common throughout the generics industry.

Animal Health grew 3.3% to €36.3 million, with contributions from multiple products across different geographic regions. The company’s top 10 products portfolio demonstrates strong diversification, with the Easyhaler® franchise, entacapone products, and various animal health medications complementing the Nubeqa® franchise.

Orion announced several significant developments during the quarter. The company appointed Berkeley Vincent as Executive Vice President of Innovative Medicines and member of the Orion Executive Team, effective April 8, 2026, signaling continued investment in its oncology capabilities.

On the regulatory front, the U.S. Food and Drug Administration granted orphan drug designation to ODM-212 for mesothelioma treatment, potentially providing marketing exclusivity and development incentives. The company also initiated the TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard treatments for patients with select advanced solid tumors.

Orion’s clinical pipeline includes multiple late-stage programs in oncology and cardiovascular disease, with partners including Bayer, MSD (Merck), and Tenax Therapeutics. The pipeline features several Phase III trials for darolutamide (Nubeqa®) in earlier-line prostate cancer settings, as well as Phase II studies for opevesostat across multiple tumor types.

The company reported progress on environmental, social, and governance metrics in its 2025 sustainability statement, prepared in accordance with European Sustainability Reporting Standards. Orion achieved a 13% reduction in Scope 1 and 2 greenhouse gas emissions compared to 2024, while maintaining high compliance rates with its Code of Conduct training (98% coverage) and Third Party Code of Conduct adherence among suppliers (96% by spend).

Management maintained its full-year 2026 guidance, projecting net sales between €1,950 million and €2,100 million, with operating profit expected in the range of €600 million to €750 million. This outlook implies continued strong growth, though at a moderating pace compared to the exceptional Q1 performance.

The stock market’s negative reaction despite strong results suggests investor concerns about several factors. Pricing erosion in the generics market, rising fixed costs, and uncertainty about the sustainability of Nubeqa®’s growth trajectory in an increasingly competitive prostate cancer treatment landscape may be weighing on sentiment. Additionally, the company faces typical pharmaceutical industry risks including patent expirations, regulatory uncertainties, and clinical trial outcomes.

Orion’s ability to maintain its current growth trajectory will likely depend on continued Nubeqa® adoption in existing markets, successful geographic expansion, positive clinical trial readouts for its pipeline assets, and effective management of cost pressures across its diversified business segments. The company is scheduled to report its half-year financial results on July 17, 2026.

Full presentation:

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.